Concepedia
Statistics
Publications
72
Citations
4K
H-Index
35
Active since
1979
Affiliations
Deciphera Pharmaceuticals (United States)(Current)
University of Kansas
The University of Texas MD Anderson Cancer Center
Monsanto (United States)
Tufts Medical Center
Daniel L. Flynn is an author at Deciphera Pharmaceuticals (United States) specializing in pharmacology, chemistry, and medicine.
Publications per year
1979–2024
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text
Medicine, Cancer Biology, Oncology +16
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations
Medicine, Oncology, Pharmacology +17
A mild two-step method for the hydrolysis of lactams and secondary amides
Daniel L. Flynn, Robert E. Zelle, Paul A. Grieco · The Journal of Organic Chemistry · 1983 · 272 citations
Natural Sciences, Chemistry, Medicinal Chemistry +6
Chemical Library Purification Strategies Based on Principles of Complementary Molecular Reactivity and Molecular Recognition
Daniel L. Flynn, J. Z. CRICH, Rajesh Devraj et al. · Journal of the American Chemical Society · 1997 · 211 citations
Pharmacy, Chemical Engineering, Chemistry +17
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 207 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +14
1–5 of 72